TY - JOUR
T1 - Bisphosphonates and glucocorticoid osteoporosis in men
T2 - results of a randomized controlled trial comparing zoledronic acid with risedronate
AU - Sambrook, Philip N
AU - Roux, Christian
AU - Devogelaer, Jean-Pierre
AU - Saag, Kenneth
AU - Lau, Chak-Sing
AU - Reginster, Jean-Yves
AU - Bucci-Rechtweg, Christina
AU - Su, Guoqin
AU - Reid, David M
N1 - Bone Volume 50, Issue 3, March 2012, Page 811
Corrigendum to “Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate” [Bone 50 (2012) 289-295] https://doi.org/10.1016/j.bone.2011.12.006
PY - 2012/1
Y1 - 2012/1
N2 - We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).
AB - We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).
U2 - 10.1016/j.bone.2011.10.024
DO - 10.1016/j.bone.2011.10.024
M3 - Article
C2 - 22061864
VL - 50
SP - 289
EP - 295
JO - Bone
JF - Bone
SN - 8756-3282
IS - 1
ER -